A subsequent study enrolled 200 patients with metastatic EGFR-mutant NSCLC and further confirmed that co-existing genomic alterations, including ERBB2 and MET amplification, negatively affected the PFS in EGFR-TKI treatment45. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.